Researchers from the University of Pennsylvania's schools of Medicine and Veterinary Medicine developed a vaccine for dogs with spontaneous non-Hodgkin's lymphoma that increased survival time. The vaccine uses the patient's own RNA and easy-to-isolate B-cells, as opposed to other attempts that used dendritic cells, which are cumbersome to produce. When relapse occurred after standard chemotherapy, 40% of the vaccinated dogs had long-term survival after a second round of chemotherapy, versus only 7% of non-vaccinated dogs.

Full Story:

Related Summaries